Home > Gastroenterology > UEGW 2024 > Irritable Bowel Syndrome: from Guar Gum to Tradipitant > Guar gum alleviates IBS-related constipation in a randomised controlled trial

Guar gum alleviates IBS-related constipation in a randomised controlled trial

Presented by
Dr Silvia Delgado-Aros, Nestle Health Sciences, Switzerland
Conference
UEGW 2024
Doi
https://doi.org/10.55788/b2c88f06

Partially hydrolysed guar gum (PHGG), a water-soluble fibre, appeared efficacious in participants with irritable bowel syndrome (IBS)-associated chronic constipation. Moreover, PHGG displayed an excellent safety profile.

“Current guidelines recommend fibre supplements as a frontline therapy for constipation, especially for individuals who do not meet the recommended daily fibre intake,” explained Dr Silvia Delgado-Aros (Nestle Health Sciences, Switzerland) [1]. “Although placebo-controlled trials show moderate evidence for the use of soluble fibres in constipation, patients with IBS-associated constipation often have a poor tolerance to these substances.” PHGG is a non-absorbable, water-soluble vegetable fibre that may be better tolerated among these patients.

A double-blind, randomised controlled trial compared the efficacy and safety of PHGG with placebo in adults with functional or IBS-associated chronic constipation. The participants (n=160) received 10 g of PHGG daily or a placebo. The primary endpoint was the frequency of spontaneous bowel movements per week after 6 weeks of therapy.

At week 6, participants in the active arm had a mean increase of 1.57 spontaneous bowel movements per week, compared with 1.14 in the placebo arm (P=0.034), meeting the primary endpoint. The responders' rate, defined as participants who had at least 3 spontaneous bowel movements per week and had an increase of at least 1 over the study period, was also higher in the active arm than in the placebo arm (34.2% vs 17.7%; P=0.018). “In practical terms, the number needed to treat in the active arm was 6,” according to Dr Delgado-Aros.

No serious adverse events (AEs) or discontinuations due to AEs were reported. The AE rates were comparable in the placebo and active arms, with 37.5% and 42.5% of the participants experiencing at least 1 AE, respectively.

“The non-absorbable water-soluble fibre PHGG seems to have a place in the fibre recommendation space for patients with functional or IBS-associated chronic constipation,” concluded Dr Delgado-Aros.


    1. Buckley MJ, et al. RCT assessing effect of 6-week intervention with 10gr daily dose of partially hydrolyzed guar gum (PHGG) on spontaneous bowel movement frequency in adults with chronic constipation. LB12, UEG Week 2024, 12–15 October, Vienna, Austria.

Copyright ©2024 Medicom Medical Publishers



Posted on